FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307023786> ?p ?o ?g. }

• W4307023786 endingPage "S116" @default.
• W4307023786 startingPage "S115" @default.
• W4307023786 abstract "BackgroundVarious approaches to dual antiplatelet therapy (DAPT) management exist to balance thrombotic and bleeding risks following acute coronary syndrome (ACS). The aim of this study was to compare and rank different DAPT management strategies in patients with ACS with or without percutaneous coronary intervention (PCI).Methods and ResultsWe conducted a systematic review with network meta-analysis of randomized controlled trials (RCTs) comparing DAPT strategies in patients with ACS. We searched MEDLINE, Embase, and CENTRAL (2007-July 2021) for RCTs that enrolled patients with ACS (or PCI with outcomes reported separately for ACS subgroup) comparing ≥2 DAPT strategies, including comparisons between P2Y12 inhibitors, empiric P2Y12 inhibitor de-escalation (switching from prasugrel- or ticagrelor-based DAPT after 1 month to clopidogrel-based DAPT to complete 12 months DAPT duration), pharmacogenomic- or platelet-function testing-guided P2Y12 inhibitor selection, or short-duration DAPT (1-3 months of DAPT followed by P2Y12 inhibitor monotherapy) with intended follow-up ≥12 months. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included all-cause death and major bleeding. We performed Bayesian network meta-analyses to compare all interventions simultaneously using the Markov-chain Monte Carlo method, conducted under the assumption of transitivity. We generated odds ratios (ORs) with 95% credible intervals (CrI) from the medians and 2.5th and 97.5th percentiles of the posterior distributions using a hierarchical Bayesian framework, using a random-effects model with informative priors for between-study heterogeneity based on pharmacological interventions with semi-objective outcomes (MACE or bleeding) or death. To rank interventions for each outcome, we calculated the mean surface under the cumulative ranking (SUCRA) curve. From 5941 articles, we included 24 RCTs enrolling 89,620 patients. Both clopidogrel- and ticagrelor-based DAPT increased MACE compared with pharmacogenomics-guided P2Y12 inhibitor selection (odds ratio [OR] 1.37, 95% credible interval [CrI] 1.08-1.74 and 1.35, 1.05-1.79, respectively) and empiric P2Y12 inhibitor de-escalation (OR 1.53, 95% CrI 1.00-2.30 and 1.51, 1.00-2.27, respectively). Compared with short-duration DAPT, standard DAPT duration with all P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) and pharmacogenomics-guided P2Y12 inhibitor selection increased major bleeding. Ticagrelor-based DAPT increased major bleeding compared with platelet function testing-guided DAPT (OR 1.60, 95% CrI 1.00-2.55). Empiric P2Y12 inhibitor de-escalation ranked best for MACE (SUCRA 0.89), whereas short-duration DAPT ranked best for death (SUCRA 0.89) and major bleeding (SUCRA 0.93).ConclusionView Large Image Figure ViewerDownload Hi-res image Download (PPT) BackgroundVarious approaches to dual antiplatelet therapy (DAPT) management exist to balance thrombotic and bleeding risks following acute coronary syndrome (ACS). The aim of this study was to compare and rank different DAPT management strategies in patients with ACS with or without percutaneous coronary intervention (PCI). Various approaches to dual antiplatelet therapy (DAPT) management exist to balance thrombotic and bleeding risks following acute coronary syndrome (ACS). The aim of this study was to compare and rank different DAPT management strategies in patients with ACS with or without percutaneous coronary intervention (PCI). Methods and ResultsWe conducted a systematic review with network meta-analysis of randomized controlled trials (RCTs) comparing DAPT strategies in patients with ACS. We searched MEDLINE, Embase, and CENTRAL (2007-July 2021) for RCTs that enrolled patients with ACS (or PCI with outcomes reported separately for ACS subgroup) comparing ≥2 DAPT strategies, including comparisons between P2Y12 inhibitors, empiric P2Y12 inhibitor de-escalation (switching from prasugrel- or ticagrelor-based DAPT after 1 month to clopidogrel-based DAPT to complete 12 months DAPT duration), pharmacogenomic- or platelet-function testing-guided P2Y12 inhibitor selection, or short-duration DAPT (1-3 months of DAPT followed by P2Y12 inhibitor monotherapy) with intended follow-up ≥12 months. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included all-cause death and major bleeding. We performed Bayesian network meta-analyses to compare all interventions simultaneously using the Markov-chain Monte Carlo method, conducted under the assumption of transitivity. We generated odds ratios (ORs) with 95% credible intervals (CrI) from the medians and 2.5th and 97.5th percentiles of the posterior distributions using a hierarchical Bayesian framework, using a random-effects model with informative priors for between-study heterogeneity based on pharmacological interventions with semi-objective outcomes (MACE or bleeding) or death. To rank interventions for each outcome, we calculated the mean surface under the cumulative ranking (SUCRA) curve. From 5941 articles, we included 24 RCTs enrolling 89,620 patients. Both clopidogrel- and ticagrelor-based DAPT increased MACE compared with pharmacogenomics-guided P2Y12 inhibitor selection (odds ratio [OR] 1.37, 95% credible interval [CrI] 1.08-1.74 and 1.35, 1.05-1.79, respectively) and empiric P2Y12 inhibitor de-escalation (OR 1.53, 95% CrI 1.00-2.30 and 1.51, 1.00-2.27, respectively). Compared with short-duration DAPT, standard DAPT duration with all P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) and pharmacogenomics-guided P2Y12 inhibitor selection increased major bleeding. Ticagrelor-based DAPT increased major bleeding compared with platelet function testing-guided DAPT (OR 1.60, 95% CrI 1.00-2.55). Empiric P2Y12 inhibitor de-escalation ranked best for MACE (SUCRA 0.89), whereas short-duration DAPT ranked best for death (SUCRA 0.89) and major bleeding (SUCRA 0.93). We conducted a systematic review with network meta-analysis of randomized controlled trials (RCTs) comparing DAPT strategies in patients with ACS. We searched MEDLINE, Embase, and CENTRAL (2007-July 2021) for RCTs that enrolled patients with ACS (or PCI with outcomes reported separately for ACS subgroup) comparing ≥2 DAPT strategies, including comparisons between P2Y12 inhibitors, empiric P2Y12 inhibitor de-escalation (switching from prasugrel- or ticagrelor-based DAPT after 1 month to clopidogrel-based DAPT to complete 12 months DAPT duration), pharmacogenomic- or platelet-function testing-guided P2Y12 inhibitor selection, or short-duration DAPT (1-3 months of DAPT followed by P2Y12 inhibitor monotherapy) with intended follow-up ≥12 months. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included all-cause death and major bleeding. We performed Bayesian network meta-analyses to compare all interventions simultaneously using the Markov-chain Monte Carlo method, conducted under the assumption of transitivity. We generated odds ratios (ORs) with 95% credible intervals (CrI) from the medians and 2.5th and 97.5th percentiles of the posterior distributions using a hierarchical Bayesian framework, using a random-effects model with informative priors for between-study heterogeneity based on pharmacological interventions with semi-objective outcomes (MACE or bleeding) or death. To rank interventions for each outcome, we calculated the mean surface under the cumulative ranking (SUCRA) curve. From 5941 articles, we included 24 RCTs enrolling 89,620 patients. Both clopidogrel- and ticagrelor-based DAPT increased MACE compared with pharmacogenomics-guided P2Y12 inhibitor selection (odds ratio [OR] 1.37, 95% credible interval [CrI] 1.08-1.74 and 1.35, 1.05-1.79, respectively) and empiric P2Y12 inhibitor de-escalation (OR 1.53, 95% CrI 1.00-2.30 and 1.51, 1.00-2.27, respectively). Compared with short-duration DAPT, standard DAPT duration with all P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) and pharmacogenomics-guided P2Y12 inhibitor selection increased major bleeding. Ticagrelor-based DAPT increased major bleeding compared with platelet function testing-guided DAPT (OR 1.60, 95% CrI 1.00-2.55). Empiric P2Y12 inhibitor de-escalation ranked best for MACE (SUCRA 0.89), whereas short-duration DAPT ranked best for death (SUCRA 0.89) and major bleeding (SUCRA 0.93). Conclusion" @default.
• W4307023786 created "2022-10-22" @default.
• W4307023786 creator A5002281990 @default.
• W4307023786 creator A5008109386 @default.
• W4307023786 creator A5057374766 @default.
• W4307023786 creator A5058218967 @default.
• W4307023786 date "2022-10-01" @default.
• W4307023786 modified "2023-10-01" @default.
• W4307023786 title "COMPARING DUAL ANTIPLATELET THERAPY STRATEGIES POST-ACUTE CORONARY SYNDROME: NETWORK META-ANALYSIS" @default.
• W4307023786 doi "https://doi.org/10.1016/j.cjca.2022.08.012" @default.
• W4307023786 hasPublicationYear "2022" @default.
• W4307023786 type Work @default.
• W4307023786 citedByCount "0" @default.
• W4307023786 crossrefType "journal-article" @default.
• W4307023786 hasAuthorship W4307023786A5002281990 @default.
• W4307023786 hasAuthorship W4307023786A5008109386 @default.
• W4307023786 hasAuthorship W4307023786A5057374766 @default.
• W4307023786 hasAuthorship W4307023786A5058218967 @default.
• W4307023786 hasBestOaLocation W43070237861 @default.
• W4307023786 hasConcept C124952713 @default.
• W4307023786 hasConcept C126322002 @default.
• W4307023786 hasConcept C142362112 @default.
• W4307023786 hasConcept C164705383 @default.
• W4307023786 hasConcept C2777698277 @default.
• W4307023786 hasConcept C2780890252 @default.
• W4307023786 hasConcept C2780980858 @default.
• W4307023786 hasConcept C500558357 @default.
• W4307023786 hasConcept C71924100 @default.
• W4307023786 hasConcept C95190672 @default.
• W4307023786 hasConceptScore W4307023786C124952713 @default.
• W4307023786 hasConceptScore W4307023786C126322002 @default.
• W4307023786 hasConceptScore W4307023786C142362112 @default.
• W4307023786 hasConceptScore W4307023786C164705383 @default.
• W4307023786 hasConceptScore W4307023786C2777698277 @default.
• W4307023786 hasConceptScore W4307023786C2780890252 @default.
• W4307023786 hasConceptScore W4307023786C2780980858 @default.
• W4307023786 hasConceptScore W4307023786C500558357 @default.
• W4307023786 hasConceptScore W4307023786C71924100 @default.
• W4307023786 hasConceptScore W4307023786C95190672 @default.
• W4307023786 hasIssue "10" @default.
• W4307023786 hasLocation W43070237861 @default.
• W4307023786 hasOpenAccess W4307023786 @default.
• W4307023786 hasPrimaryLocation W43070237861 @default.
• W4307023786 hasRelatedWork W2106217940 @default.
• W4307023786 hasRelatedWork W2150858828 @default.
• W4307023786 hasRelatedWork W2538235438 @default.
• W4307023786 hasRelatedWork W2759749682 @default.
• W4307023786 hasRelatedWork W3027376345 @default.
• W4307023786 hasRelatedWork W3119665449 @default.
• W4307023786 hasRelatedWork W3129961335 @default.
• W4307023786 hasRelatedWork W3134665543 @default.
• W4307023786 hasRelatedWork W3135788989 @default.
• W4307023786 hasRelatedWork W3153940088 @default.
• W4307023786 hasVolume "38" @default.
• W4307023786 isParatext "false" @default.
• W4307023786 isRetracted "false" @default.
• W4307023786 workType "article" @default.